使用大型语言模型评估公众对社交媒体上类似葡萄糖-1受体激动剂的看法
Sulaiman Somani1, Sneha S Jain2, Ashish Sarraju3
1Department of Medicine, Stanford University, Stanford, CA, USA.
Communications medicine
|July 10, 2024
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 显示出公众对减肥和心血管益处的高度兴趣. 对Reddit讨论的分析揭示了包括副作用,访问和心理影响在内的关键话题.
科学领域:
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
- 数字健康数字健康
背景情况:
- 全球肥胖率的上升带来了重大的公共卫生挑战.
- 肥胖与心血管疾病增加和高医疗保健成本有关.
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 对于减肥和降低心血管风险是有效的.
研究的目的:
- 在Reddit上分析围绕GLP-1RAs的公共话语.
- 确定关于GLP-1 RA使用的关键主题和公众情绪.
- 了解患者的经验超出临床试验数据.
主要方法:
- 利用人工智能和大型语言模型进行主题建模.
- 分析了39万多个与GLP-1RA相关的Reddit讨论.
- 采用先进的人工智能来分类和解释用户生成的内容.
主要成果:
- 确定了168个与GLP-1RA相关的主题和33个讨论小组.
- 关键主题包括减肥,副作用比较,获取/供应问题和心理益处.
- 在网上讨论中,公众对GLP-1RA的情绪主要是中立到积极的.
结论:
- 公共在线讨论提供了对现实世界GLP-1RA经验的见解.
- 研究结果强调需要监测临床试验中未发现的副作用.
- 该研究强调了药物获取和供应链问题的公共卫生影响.
相关概念视频
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
Hypoglycemia and Glucagon
254
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
254
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K


